New research indicates that treatment with the investigational anti-amyloid drug Tarenflurbil appears to be well-tolerated in patients with mild to moderate Alzheimer’s disease and may exert a dose-related effect on measures of daily activities and global function in patients with mild AD.

From our partners at VerusMed
verusmed.com

Sponsored by The Doctor’s Channel